BIAFbioAffinity Technologies, Inc.
- BusinessWire
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
CyPath® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79% year-to-date Company advances precision medicine pipeline with ...
- BusinessWire
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
Benefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 "Battle of the Blues" EventIn recognition of National Lung Cancer Awareness Month, bioAffinity ...
- BusinessWire
bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to address current challenges in pulmonary nodule management and to discuss preliminary ...
- BusinessWire
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets Company advances research and development in diagnostic tests for major lung ...
- PR Newswire
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 9, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a ...
- BusinessWire
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its ...
- PR Newswire
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 8, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a ...
- BusinessWire
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into ...
- BusinessWire
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia Patent strategy protects proprietary CyPath Lung flow cytometry+AI approach in international ...
- BusinessWire
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
Nearly 90% increase in number of physician offices using CyPath Lung Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by nearly 50% bioAffinity Technologies, Inc. (NASDAQ:BIAF, ...
- BusinessWire
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
Companies debut federal distribution collaboration to VA leadership, administrators and physicians at NAVREF 2026bioAffinity engages GO2 for Lung Cancer network to broaden outreach to veterans at riskbioAffinity ...
- BusinessWire
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
Presentations demonstrate beneficial role for CyPath Lung in veteran lung cancer care NAVREF 2026 focuses on innovative research to improve healthcare for veterans bioAffinity Technologies, Inc. (NASDAQ:BIAF, ...
- GlobeNewswire
Four High-Impact Small Caps Enter the Spotlight
DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The small-cap market is delivering a mix of catalysts, with the following companies in particular putting substantial new developments in front of investors: Aethlon Medical ...
- BusinessWire
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds of lung cancer cases worldwide bioAffinity Technologies, Inc. ...
- GlobeNewswire
Four Biotech Stories Heating Up Right Now
DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies ...
- BusinessWire
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
BIAF continues to be listed and traded on Nasdaq bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of ...
- BusinessWire
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced that President and CEO ...
- BusinessWire
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
More than 680,000 Americans living with a history of lung cancer represent a significant population requiring ongoing surveillance Noninvasive CyPath® Lung has the potential to complement imaging in monitoring for ...
- BusinessWire
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse ...
- BusinessWire
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide Agreement significantly expands bioAffinity's commercial reach through ...
- PR Newswire
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), ...
- BusinessWire
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement ...
- PR Newswire
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
JERSEY CITY, N.J., , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, ...
- BusinessWire
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities purchase agreement with ...
- BusinessWire
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and advances longitudinal clinical trial Pipeline expands to include development of precision ...